Evolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET
Company Participants
Nareg Sagherian - VP and Head of Global IR and Corporate Communications
David Moatazedi - President and CEO
Rui Avelar - Chief Medical Officer and Head of R&D
Sandra Beaver - CFO
Conference Call Participants
Annabel Samimy - Stifel
Navann Ty - BNP Paribas
Doug Tsao - H.C. Wainwright
Operator
Good afternoon, everyone, and thank you for standing by. Welcome to Evolus Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. [Operator Instructions]. As a reminder, today's conference is being recorded and webcast live.
I would now like to turn the conference over to Nareg Sagherian, Vice President and Head of Global Investor Relations and Corporate Communications. Please go ahead.
Nareg Sagherian
Thank you, operator, and welcome to everyone joining us on today's call to review Evolus' third quarter 2024 financial results. Our third quarter 2024 press release is now on our website at evolus.com. With me today are David Moatazedi, President and Chief Executive Officer; Rui Avelar, Chief Medical Officer and Head of R&D'; and Sandra Beaver, Chief Financial Officer. Today's call will include forward-looking statements. Actual results may differ materially due to the risks and uncertainties outlined in our earnings press release and SEC filings.
These forward-looking statements are based on current assumptions, and we undertake no obligation to update them. Additionally, we will discuss certain non-GAAP financial measures. These measures should be considered in addition to and not as a substitute for our GAAP results.
A reconciliation of GAAP to non-GAAP measures is included in today's earnings release. As a reminder, our earnings release and SEC filings are available on the SEC's website and on our investor relations website. Following the conclusion of today's call, a replay will be available on our website at investors.evolus.com.
With that, I'll turn the call over to our CEO, David Moatazedi.
David Moatazedi
Thank you, Nareg. Good afternoon, everyone. Thank you for joining us on our third quarter 2024 earnings conference call. In our fifth year of commercialization, Evolus has evolved from a single product company to a multi-product portfolio with last week's approval of Estyme in Europe. This important milestone positions us as only one of five companies globally offering a portfolio of injectable aesthetic products. Our experience in Europe with Estyme will inform our U.S. introduction of Evolysse.